JPRN-UMIN000009966招募中未知
A Multicenter phase II study of Docetaxel combined with Bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer. - Phase II study of Docetaxel plus Bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous NSCLC.
Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University0 个研究点目标入组 20 人开始时间: 2013年2月6日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Squamous metastasis (2) No prior platinum-based chemotherapy as first- line therapy (3) No prior docetaxel or bevacizumab as first- line therapy (4) Having serious complications. ex): a serious heart disease , cerebrovascular disorder, diabetes that it is hard to control or hypertention , a severe infection, pulmonary fibrosis, interstitial pneumonia, respiratory failure, bleeding, a large quantity of hydrothorax or abdominal dropsy retention, peptic ulcer of the activity, serious nerve disease (5) Symptomatic brain metastasis (6) With pulmonary cavitary lesions (7) Have an anamnesis and the complications , expectoration of fresh blood more than 2.5 ml due to non-small-cell lung cancer (8) Having an anamnesis of the following bloody phlegm or complications * there is the dosage career when bloody phlegm occurring continuously (more than one week) or the anamnesis or the internal use styptic is continuous(the cases that an internal use styptic was necessary for again after having been relieved using an internal use styptic or the bloody phlegm which needs with a history of bloody phlegm, the dosage of the injection styptic to need the dosage or the dosage) (9) Uncontrollable hypertension (10) Current or previous (within the last 1 year) history of GI perforation (11) The operation has been scheduled for the examination period (12) Have multiple primary cancer (13) History of serious drug hypersensitivity (14) Pregnancy or lactation (15) Active psychological disease (16) Patients who have received a radiation therapy in chest (17) Receives the steroid continuously(p.o. or i.v.) (18) Any other medical condition that makes the patient unsuitable for inclusion in the study according to the opinion of the investigator
研究者
相似试验
已完成
2 期
Randomised Phase II study of combined Docetaxel and Nedaplatin versus Docetaxel alone chemotherapy in advanced or recurrent esophageal cancerAdvanced or recurrent esophageal cancerJPRN-UMIN000005877Toho University43
进行中（未招募）
不适用
Multicenter phase II study evaluating docetaxel, CDDP, and cetuximab as induction regimen prior to surgery in chemonaive patients with NSCLC stage IB, II, and IIIA. - INN06eoadjuvant treatment of non-small lung cancerEUCTR2006-004639-31-ATTAKO
已完成
2 期
A randomized phase 2 study of Docetaxel with or without Bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced non-squamous non-small-cell lung canceron-small cell lung cancerJPRN-UMIN000004715West Japan Oncology Group100
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - DOCOX GASTRIC (Docetaxel-Oxaliplatin in Gastric Cancer)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-HUSanofi-aventis groupe270
进行中（未招募）
不适用
A randomized phase II study of docetaxel in combination with oxaliplatin with or without 5-FU or capecitabine in metastatic or locally recurrent gastric cancer previously untreated with chemotherapy for advanced disease. - GATE (GAstric cancer study with Taxotere-Eloxatin-based regimens)Metastatic or local recurrent gastric cancer previously untreated with chemotherapy for advance disease.MedDRA version: 8.1Classification code 10017758EUCTR2005-005464-92-BESanofi-aventis groupe270